Cargando…

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer

Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Qi, Sathe, Anuja, Black, Peter C., Goebell, Peter J., Kamat, Ashish M., Schmitz-Draeger, Bernd, Nawroth, Roman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409046/ https://www.ncbi.nlm.nih.gov/pubmed/28516152 http://dx.doi.org/10.3233/BLC-170105

Ejemplares similares

New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21–23, 2017
por: Black, Peter C., et al.
Publicado: (2018)

Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
por: Tong, Zhichao, et al.
Publicado: (2019)

Approach to the Treatement of Metabolic Syndrome
por: Aganović, Izet, et al.
Publicado: (2007)

A perturbation treatement of non-linear restoring forces
por: Cole, F, et al.
Publicado: (1953)

Psychiatric Adverse Effects of treatement with Corticosteroids: A Tunisian case report
por: Boussaid, N., et al.
Publicado: (2023)

The effect of iterative solutions in the quasi-adiabatic treatement of transfer reactions involving deuterons
por: Mustafa, Y, et al.
Publicado: (1998)

Fast processors for on-line treatement of data from high-energy physics experiments
por: Fucci, A, et al.
Publicado: (1975)

Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example
por: Sekula, Peggy, et al.
Publicado: (2016)

Functional outcome in patients following cartilage regenerative treatement: outcome at minimum follow-up of 12 months
por: Zantop, Thore, et al.
Publicado: (2020)

Bladder cancer: 2017 and beyond
por: Kamat, Ashish M.
Publicado: (2017)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease
por: Kamat, Ashish M.
Publicado: (2021)

The Prognostic Role of CDK9 in Bladder Cancer
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

Advances in risk stratification of bladder cancer to guide personalized medicine
por: Matulay, Justin T., et al.
Publicado: (2018)

Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov
por: Kunath, Frank, et al.
Publicado: (2013)

Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer
por: Agarwal, Piyus K., et al.
Publicado: (2008)

Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination
por: Jinesh G., Goodwin, et al.
Publicado: (2012)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markers
por: Bonato, Matteo, et al.
Publicado: (2017)

New discoveries in the molecular landscape of bladder cancer
por: Li, Roger, et al.
Publicado: (2016)

IMPACT OF NONINVASIVE VENTILATION IN THE TREATEMENT OF ACUTE HYPOXIC RESPIRATORY FAILURE DURING COVID-19 PANDEMIC: RETROSPECTIVE STUDY AT A COMMUNITY TEACHING HOSPITAL IN CHICAGO
por: BUDDHARAJU, VENKATA, et al.
Publicado: (2021)

Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2
por: Makarević, Jasmina, et al.
Publicado: (2014)

Non-invasive imaging of engineered human tumors in the living chicken embryo
por: Jefferies, Benedict, et al.
Publicado: (2017)

STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy
por: Hindupur, Sruthi V., et al.
Publicado: (2020)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients
por: Krughoff, Kevin, et al.
Publicado: (2015)

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
por: Nawroth, Roman, et al.
Publicado: (2011)

Non‐metabolic function of MTHFD2 activates CDK2 in bladder cancer
por: Liu, Xi, et al.
Publicado: (2021)

Variant histology in bladder cancer: diagnostic and clinical implications
por: Black, Anna J., et al.
Publicado: (2020)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
por: Kwiatkowski, Nicholas, et al.
Publicado: (2014)

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus
por: Koch, Jana, et al.
Publicado: (2022)

Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells
por: TAKEUCHI, HISASHI, et al.
Publicado: (2015)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pa39p52tjk3tmldkl80kch3eg5